|
May 30
|
MediPharm Labs Refuses to Answer Direct Questions Regarding Credible Securities Fraud Allegations Says Apollo Capital
|
|
May 30
|
Apollo Capital alleges securities fraud at Medipharm Labs
|
|
May 29
|
MediPharm Labs Responds to Fabricated Allegations from Dissident Shareholder
|
|
May 29
|
Alleged Securities Fraud at MediPharm Labs Says Apollo Capital
|
|
May 28
|
MediPharm Labs Board Issues Letter to Shareholders in Response to Inadequate Dissident Plan
|
|
May 27
|
Apollo Capital Calls Out MediPharm Chairman Chris Taves (Managing Director, BMO Capital Markets) for Failure to Properly Communicate to Shareholders Details of David Pidduck’s Past as CEO and VP of Marketing for OxyContin® Manufacturer Purdue Pharma
|
|
May 26
|
MediPharm Labs Begins Production of First Order for International Expansion of Novel Cannabis Metered Dose Portfolio in the EU and United Kingdom Under Blackpoint Sales and Distribution Agreement
|
|
May 23
|
MediPharm Labs Cautions Shareholders about Dissident Nominees’ Governance Failures at Check-Cap Ltd.
|
|
May 23
|
Apollo Capital Comments on MediPharm Labs’ Failure to Respond to Reasonable Offer to Ensure Fair, Lawful and Transparent 2025 Annual Meeting
|
|
May 22
|
MediPharm Achieves Key Milestone Toward $4.5 Million Cash Sale of Hope Facility, On Track to Close in June
|
|
Feb 10
|
Promising TSX Penny Stocks To Consider In February 2025
|
|
Feb 10
|
MediPharm Labs Announces Termination of the Proposed Sale of Napanee Facility to Kensana Health
|
|
Dec 23
|
TSX Penny Stocks With Market Caps Over CA$20M To Consider
|
|
May 8
|
MediPharm Labs Sets Date to Report First Quarter 2024 Financial Results
|
|
Dec 22
|
MediPharm Labs Provides Update on Board of Directors and Long Term Incentive Program
|
|
Nov 8
|
MediPharm Labs Sets Date to Report Third Quarter 2023 Financial Results
|